Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro

International Journal for Vitamin and Nutrition Research

Volumn 80, Issue 3, 2010, Pages 168-177

  Han, Yi ^a   Liu, Yuan ^a   Mi, Qiongyu ^a   Xie, Liping ^a   Huang, Yan ^a   Jiang, Qin ^a   Chen, Qi ^a   Ferro, Albert ^b   Liu, Naifeng ^a   Ji, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced glycation end products; Nitric oxide synthase; Platelet; Pyridoxine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIDOXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; IN VITRO STUDY; MALE; RADIOIMMUNOASSAY; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; WESTERN BLOTTING;

ADULT; BLOOD PLATELETS; CYCLIC GMP; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; FEMALE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDOXINE; SERUM ALBUMIN; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 78751629084     PISSN: 03009831     EISSN: None     Source Type: Journal    
DOI: 10.1024/0300-9831/a000019     Document Type: Article

References (41)

1. Ahmad, I., Hoessli, D.C., Walker-Nasir, E., Choudhary, M.I., Rafik, S.M., Shakoori, A.R. and Nasir-ud-Din, ( 2006) Phosphorylation and glycosylation interplay: protein modifications at hydroxy amino acids and prediction of signaling functions of the human beta3 integrin family. J. Cell. Biochem. 99, 706-18.
2. Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and Hemmings, B.A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-51.
3. Boushey, C.J., Beresford, S.A., Omenn, G.S. and Motulsky, A.G. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-57.
4. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-20.
5. Bucala, R., Tracey, K.J. and Cerami, A. (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87, 432-8.
6. Chen, L., Liu, Y., Cui, B., Mi, Q., Huang, Y., Fan, L., Chen, Q., Tang, J., Ferro, A. and Ji, Y. (2007) 17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. Clin. Exp. Pharmacol. Physiol. 34, 972-8.
7. Chi, M.S. (1984) Vitamin B6 in cholesterol metabolism. Nutr. Res. 4, 359-62.
8. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., De Cesare, D., De Blasis, G., Muraro, R., Bei, R., Chiarelli, F., Schmidt, A.M., Cuccurullo, F. and Mezzetti, A. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108, 1070-7.
9. D'Angelo, A. and Selhub, J. (1997) Homocysteine and thrombotic disease. Blood 90, 1-11.
10. Dav̀ G. and Patrono, C. (2007) Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-94.
11. Dimmeler, S., Assmus, B., Hermann, C., Haendeler, J. and Zeiher, A.M. (1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ. Res. 83, 334-41.
12. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A.M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-5. (Pubitemid 29279182)
13. Eikelboom, J.W., Lonn, E., Genest, J., Jr., Hankey, G. and Yusuf, S. (1999) Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131, 363-75.
14. Freedman, J.E., Loscalzo, J., Barnard, M.R., Alpert, C., Keaney, J.F. and Michelson, A.D. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 100, 350-6.
15. Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K., Franke, T.F., Papapetropoulos, A. and Sessa, W.C. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601.
16. Gallis, B., Corthals, G.L., Goodlett, D.R., Ueba, H., Kim, F., Presnell, S.R., Figeys, D., Harrison, D.G., Berk, B.C., Aebersold, R. and Corson, M.A. (1999) Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem. 274, 30101-8.
17. Hangaishi, M., Taguchi, J., Miyata, T., Ikari, Y., Togo, M., Hashimoto, Y., Watanabe, T., Kimura, S., Kurokawa, K. and Ohno, M. (1998) Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem. Biophys. Res. Commun. 248, 285-92.
18. Ji, Y., Diao, J., Han, Y., Huang, Y., Bai, H., Chen, Q., Fan, L. and Ferro, A. (2006) Pyridoxine prevents dysfunction of endothelial cell nitric oxide production in response to low-density lipoprotein. Atherosclerosis 188, 84-94. (Pubitemid 44164409)
19. Ji, Y., Han, Y., Diao, J., Huang, Y., Chen, Q. and Ferro, A. (2003) Rabbit aortic endothelial dysfunction by low-density lipoprotein is attenuated by L-arginine, L-ascorbate and pyridoxine. Br. J. Pharmacol. 140, 1272-82.
20. Ji, Y., Han, Y., Diao, J., Huang, Y., Chen, Q. and Ferro, A. (2004) Inhibition of endothelial nitric oxide generation by low-density lipoprotein is partially prevented by L-arginine and L-ascorbate. Atherosclerosis 176, 345-53.
21. Anonymous (1981) Is vitamin B6 an antithrombotic agent? Lancet 1, 1299-300.
22. Levene, C.I. and Murray, J.C. (1977) The aetiological role of maternal vitamin-B6 deficiency in the development of atherosclerosis. Lancet 1, 628-30.
23. Malinow, M.R., Bostom, A.G. and Krauss, R.M. (1999) Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99, 178-82.
24. Moore, S.D. and Prevelige, P.E., Jr. ( 2002) DNA packaging: a new class of molecular motors. Curr. Biol. 12, R96-8.
25. Moro, M.A., Russel, R.J., Cellek, S., Lizasoain, I., Su, Y., Darley-Usmar, V.M., Radomski, M.W. and Moncada, S. (1996) cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U.S.A. 93, 1480-5.
26. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I. and Brownlee, M. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-90. (Pubitemid 30212409)
27. Radomski, M.W., Palmer, R.M. and Moncada, S. (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U.S.A. 87, 5193-7.
28. Sakata, N., Meng, J. and Takebayashi, S. (2000) Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J. Atheroscler. Thromb. 7, 169-76.
29. Schmidt, A.M., Yan, S.D., Brett, J., Mora, R., Nowygrod, R. and Stern, D. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 91,2155-68.
30. Selhub, J. (1999) Homocysteine metabolism. Annu. Rev. Med. 19, 217-246.
31. Snyder, S.H. and Jaffrey, S.R. (1999) Vessels vivified by Akt acting on NO synthase. Nat. Cell. Biol. 1, E95-6.
32. Ueland, P.M., Refsum, H., Beresford, S.A. and Vollset, S.E. (2000) The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 72, 324-32.
33. Vanhaesebroeck, B. and Alessi, D.R. 2000. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561-76.
34. Vosseller, K., Wells, L., Lane, M.D. and Hart, G.W. (2002) Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 99, 5313-8.
35. Walker, K.S., Deak, M., Paterson, A., Hudson, K., Cohen, P. and Alessi, D.R. (1998) Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem. J. 331, 299-308. (Pubitemid 128705836)
36. Wells, L., Vosseller, K. and Hart, G.W. (2001) Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291, 2376-8.
37. Wu, Y., Liu, Y., Han, Y., Cui, BT., Mi, Q., Huang, Y., Wang, L., Jiang, Q., Chen, Q., Liu, NF., Ferro, Q. and Ji, Y. (2010) Pyridoxine increases nitric oxide biosynthesis in human platelets. Int. J. Vitam. Nutr. Res. 79, 95-103.
38. Xu, B., Chibber, R., Ruggiero, D., Kohner, E., Ritter, J. and Ferro, A. (2003) Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 17, 1289-91.
39. Xu, B., Ji, Y., Yao, K., Cao, Y.X. and Ferro. A. (2005) Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin. Sci. (Lond). 109, 439-46.
40. Yamagishi, S., Ueda, S. and Okuda, S. (2007) A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Med. Hypotheses 69, 922-4.
41. Yamagishi, S.I., Edelstein, D., Du, X.L. and Brownlee, M. (2001) Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 50, 1491-4. (Pubitemid 32500184)